Morgan Stanley Cti Biopharma Corp Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.2 - $6.01 $302,059 - $432,233	71,919 Added 11.15%	716,710 $3.01 Million
Q4 2022 Feb 14, 2023	SELL	$4.45 - $6.17 $361,847 - $501,707	-81,314 Reduced 11.2%	644,791 $3.88 Million
Q3 2022 Nov 14, 2022	SELL	$5.36 - $7.43 $777,151 - $1.08 Million	-144,991 Reduced 16.64%	726,105 $4.23 Million
Q2 2022 Oct 27, 2022	BUY	$3.55 - $6.27 $2.84 Million - $5.01 Million	798,845 Added 1105.65%	871,096 $5.2 Million
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $2.84 Million - $5.01 Million	798,845 Added 1105.65%	871,096 $5.2 Million

Q1 2022 Oct 27, 2022	SELL	$1.9 - $5.23 $1.52 Million - $4.18 Million	-798,845 Reduced 91.71%	72,251 $338,000
Q1 2022 May 13, 2022	SELL	$1.9 - $5.23 $51,849 - $142,721	-27,289 Reduced 27.42%	72,251 $338,000
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.86 $657,989 - $1.31 Million	-456,937 Reduced 82.11%	99,540 $247,000
Q3 2021 Nov 15, 2021	BUY	$2.25 - $3.18 $1.25 Million - $1.77 Million	556,477 New	556,477 $1.64 Million

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.